Philip P. Boudreau, Executive Vice President and CFO of Abbott Laboratories, filed a Form 4 on September 3, 2026, reporting a disposition of common shares on September 1, 2026.
Key Highlights
- Reporting person: Philip P. Boudreau, EVP and CFO of Abbott Laboratories (NYSE:ABT).
- Transaction: 388 common shares without par value were disposed of (Code F) on September 1, 2026, at a price of $110.36 per share.
- Direct holdings after transaction: 70,784 common shares held directly following the reported transaction.
- Indirect holdings - Profit Sharing Trust: 9,332 shares held indirectly through the Abbott Laboratories Stock Retirement Trust as of September 1, 2026.
- Indirect holdings - spouse: 2,200 common shares held indirectly by spouse.
- No derivative securities: No derivative security transactions were reported in Table II.
Abbott CFO Boudreau Disposes of 388 Shares at $110.36
According to the Form 4 filing submitted to the SEC on September 3, 2026, Philip P. Boudreau, who serves as Executive Vice President and Chief Financial Officer of Abbott Laboratories, reported a single transaction involving common shares without par value. On September 1, 2026, Boudreau disposed of 388 shares under transaction code F at a price of $110.36 per share. Transaction code F typically indicates shares withheld by the issuer to cover tax obligations related to the vesting or exercise of equity awards, as described in SEC Form 4 instructions.
Following the reported transaction, Boudreau directly beneficially owned 70,784 common shares of Abbott Laboratories, according to the filing. In addition to his direct holdings, the filing discloses two categories of indirect beneficial ownership: 9,332 shares held through the Abbott Laboratories Stock Retirement Trust, described in the filing as the balance in the trust as of September 1, 2026, and 2,200 shares held indirectly by his spouse. No derivative securities were reported in Table II of the form.
The form was signed by Jessica H. Paik as Attorney-in-Fact for Philip P. Boudreau, and the filing date is recorded as September 3, 2026. The filing indicates Boudreau filed as one reporting person and is identified as an officer of the issuer. No Rule 10b5-1 plan designation was checked on the form.
What Was Disclosed
Abbott Laboratories CFO Philip P. Boudreau reported the disposal of 388 common shares at $110.36 on September 1, 2026, leaving him with 70,784 shares held directly, plus indirect holdings through a profit sharing trust and by his spouse.



Please wait processing your request...